← Leaderboards
Marni E Harris-White
University Of California Los Angeles
$2,600,591
Attributed
$3,851,207
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $745.3K · FY2005–16$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$3,851,207 · 5
VA$0 · 1
By mechanism
R44$1,489,893 · 1
R01$1,349,974 · 1
R43$1,011,340 · 3
I01$0 · 1
Top collaborators
- Somasundar Prasad Gabbita4 shared
- Frank Zemlan1 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Zhefeng Guo$3,623,579
- David W Walker$10,114,526
- David Eisenberg$31,979,624
- Yvonne Yu-Hsuan Chen$4,496,748
- Mai Brooks$1,438,803
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseAmyloid Beta-ProteinFunctional DisorderNerve DegenerationBrainChronicDisease ProgressionPathologyPeripheralEvaluationTumor Necrosis Factor-AlphaRattusResponseSmall MoleculeClinical ResearchFda ApprovedAcuteNeurologicNeurotoxicMemory ImpairmentLeadMouse ModelEnzyme-Linked Immunosorbent Assay
Grant awards (14)
A Novel Small molecule TNF-alpha inhibitor as a disease-modifying AD drug treatment.$744,572
R44 · FY2016 · AG
A Novel Small molecule TNF-alpha inhibitor as a disease-modifying AD drug treatment.$745,321
R44 · FY2015 · AG
Novel Alzheimer's Disease Drug Treatment$224,905
R43 · FY2014 · AG
TBI Neuroimmune Dysregulation as a Prodrome to Alzheimer?s Disease$0
I01 · FY2014 · VA · contact PI
A first-in-class orally active anti-TNF-alpha inhibitor to treat AD$395,476
R43 · FY2013 · AG
TBI Neuroimmune Dysregulation as a Prodrome to Alzheimer?s Disease$0
I01 · FY2013 · VA · contact PI
A Novel Small molecule TNF?? inhibitor as a disease-modifying AD drug treatment.$390,959
R43 · FY2012 · AG
TBI Neuroimmune Dysregulation as a Prodrome to Alzheimer?s Disease$0
I01 · FY2012 · VA · contact PI
TBI Neuroimmune Dysregulation as a Prodrome to Alzheimer?s Disease$0
I01 · FY2011 · VA · contact PI
Carrier Mediated Uptake of ABeta In Vivo & In Vitro$260,744
R01 · FY2007 · AG · contact PI
Carrier Mediated Uptake of ABeta In Vivo & In Vitro$268,532
R01 · FY2006 · AG · contact PI
Carrier Mediated Uptake of ABeta In Vivo &In Vitro$274,995
R01 · FY2005 · AG
Carrier Mediated Uptake of ABeta In Vivo &In Vitro$274,995
R01 · FY2004 · AG
Carrier Mediated Uptake of ABeta In Vivo &In Vitro$270,708
R01 · FY2003 · AG